Reimbursement Intelligence Digest — Week of July 27, 2026
### Actions Required This Week **Infectious Disease** - Review the FDA approval of REZZAYO (REZAFUNGIN) as a new molecular entity per policy FDA-NDA
Digest for the Week of July 27, 2026
Actions Required This Week
Sign in to read the full article
Create a free account to access the complete analysis, action recommendations, and related alert references.
Quick answers
What actions are required for the new drug REZZAYO in Infectious Disease?
Review the FDA approval under policy FDA-NDA217417 and ensure that coding reflects its status as a novel entity.
What updates are necessary following the FDA approval of ILUMYA in Dermatology?
Update billing systems to include ILUMYA as a newly approved molecular entity, reflecting compliance with FDA-BLA761067.
How should coding teams respond to proposed LCD changes for Oxygen Equipment in DME?
Teams should review and provide comments on proposed LCD DL33797 before the deadline specified within the document.
What documentation changes are needed for Pain Management under LCD updates?
Ensure that procedural documentation aligns with the updated requirements of LCD L33912 and L35010 for Trigger Point Injections.
Content summarized from publicly available federal publications including CMS, MAC contractors, and the Federal Register. CLV Intelligence is not affiliated with or endorsed by any government agency. This is not legal or medical advice.